| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Pomalidomide-C5-azide targets cereblon (CRBN), an E3 ubiquitin ligase substrate receptor. The pomalidomide moiety binds to CRBN, recruiting the E3 ubiquitin ligase complex to proteins of interest when incorporated into a PROTAC molecule. This enables targeted protein degradation via the ubiquitin-proteasome system. The azide group provides a handle for click chemistry conjugation to other molecular components.
|
|---|---|
| ln Vitro |
In vitro, Pomalidomide-C5-azide is used as a building block in the synthesis of PROTAC molecules. The azide group allows for copper-catalyzed azide-alkyne cycloaddition (CuAAC) or strain-promoted azide-alkyne cycloaddition (SPAAC) reactions to attach the ligand-linker conjugate to target protein-binding moieties. The pomalidomide-CRBN interaction enables the recruitment of the E3 ubiquitin ligase machinery for targeted protein degradation.
|
| ln Vivo |
In vivo activity is not directly applicable for Pomalidomide-C5-azide as it is a synthetic intermediate used in PROTAC synthesis. The PROTACs synthesized using this building block are then evaluated in vivo for targeted protein degradation and therapeutic efficacy. The pomalidomide-based CRBN ligand provides a well-validated E3 ligase recruitment moiety for PROTAC applications.
|
| Enzyme Assay |
Non-cellular assays for Pomalidomide-C5-azide involve characterizing its chemical properties and reactivity. The azide group's reactivity can be assessed by monitoring click chemistry conjugation reactions using HPLC or mass spectrometry. Binding affinity to CRBN can be measured using techniques such as fluorescence polarization or surface plasmon resonance. The compound's purity is confirmed by HPLC, and its structure is verified by NMR and mass spectrometry.
|
| Cell Assay |
In vitro cellular experiments are not performed with Pomalidomide-C5-azide directly, as it is a synthetic intermediate. Rather, the PROTACs synthesized using this building block are tested in cellular assays to assess target protein degradation (by Western blotting), downstream signaling effects, and cell viability. The CRBN-binding pomalidomide moiety enables efficient E3 ligase recruitment in the final PROTAC molecule.
|
| Animal Protocol |
In vivo animal experiments are performed with PROTACs synthesized using Pomalidomide-C5-azide, not with the building block itself. These studies are conducted in murine xenograft models to evaluate the antitumor efficacy, pharmacokinetics, and safety of the final PROTAC molecules. The pomalidomide-based CRBN ligand contributes to the overall activity of the PROTAC.
|
| ADME/Pharmacokinetics |
Pomalidomide-C5-azide has a molecular formula of C18H20N6O4 and a molecular weight of 384.39. The CAS number is 2434629-02-2. The compound is also known as 4-((5-Azidopentyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione. Purity is typically ≥98%. The compound is stored according to the manufacturer's recommendations. It is soluble in DMSO and other organic solvents suitable for PROTAC synthesis.
|
| Toxicity/Toxicokinetics |
Toxicity data for Pomalidomide-C5-azide are limited as it is a research reagent used in PROTAC synthesis, not a therapeutic agent. Standard laboratory safety precautions should be followed when handling this compound. The azide group may pose a hazard if heated or subjected to shock. The compound is for research use only and not for human therapeutic applications.
|
| References | |
| Additional Infomation |
Pomalidomide-C5-azide is an E3 ligase ligand-linker conjugate for PROTAC synthesis. The azide group enables click chemistry conjugation. The compound is classified as a PROTAC E3 ligand-linker conjugate. All products are for research use only and not for human therapeutic applications.
|
| Exact Mass |
384.155
|
|---|---|
| CAS # |
2434629-02-2
|
| PubChem CID |
152396664
|
| Appearance |
Light yellow to yellow solid powder
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
28
|
| Complexity |
704
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)NCCCCCN=[N+]=[N-]
|
| InChi Key |
XINWYKDRHLFQFY-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H20N6O4/c19-23-21-10-3-1-2-9-20-12-6-4-5-11-15(12)18(28)24(17(11)27)13-7-8-14(25)22-16(13)26/h4-6,13,20H,1-3,7-10H2,(H,22,25,26)
|
| Chemical Name |
4-(5-azidopentylamino)-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Typically soluble in DMSO (e.g. 10 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
